Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Identifieur interne : 000436 ( Ncbi/Curation ); précédent : 000435; suivant : 000437Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Auteurs : Vincent Paillé [France] ; Philippe Brachet ; Philippe DamierSource :
- Neuroreport [ 0959-4965 ] ; 2004.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (pharmacology), Behavior, Animal (drug effects), Behavior, Animal (physiology), Cell Count, Dyskinesias (physiopathology), Immunohistochemistry, Levodopa (pharmacology), Male, Oxidopamine, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (pathology), Parkinson Disease, Secondary (physiopathology), Rats, Rats, Sprague-Dawley, Substantia Nigra (pathology), Substantia Nigra (physiopathology), Sympatholytics, Tyrosine 3-Monooxygenase (metabolism).
- MESH :
- chemical , metabolism : Tyrosine 3-Monooxygenase.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal.
- pathology : Parkinson Disease, Secondary, Substantia Nigra.
- physiology : Behavior, Animal.
- physiopathology : Dyskinesias, Parkinson Disease, Secondary, Substantia Nigra.
- Animals, Cell Count, Immunohistochemistry, Male, Oxidopamine, Rats, Rats, Sprague-Dawley, Sympatholytics.
Abstract
The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias. We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.
PubMed: 15094523
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001034
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000F93
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F93
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000436
Links to Exploration step
pubmed:15094523Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paillé">Vincent Paillé</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet, 44093 Nantes, France. vpaille@nantes.inserm.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet, 44093 Nantes</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15094523</idno>
<idno type="pmid">15094523</idno>
<idno type="wicri:Area/PubMed/Corpus">001034</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001034</idno>
<idno type="wicri:Area/PubMed/Curation">000F93</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F93</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F93</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F93</idno>
<idno type="wicri:Area/Ncbi/Merge">000436</idno>
<idno type="wicri:Area/Ncbi/Curation">000436</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paillé">Vincent Paillé</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet, 44093 Nantes, France. vpaille@nantes.inserm.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet, 44093 Nantes</wicri:regionArea>
<placeName><region type="region" nuts="2">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
</author>
</analytic>
<series><title level="j">Neuroreport</title>
<idno type="ISSN">0959-4965</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Behavior, Animal (drug effects)</term>
<term>Behavior, Animal (physiology)</term>
<term>Cell Count</term>
<term>Dyskinesias (physiopathology)</term>
<term>Immunohistochemistry</term>
<term>Levodopa (pharmacology)</term>
<term>Male</term>
<term>Oxidopamine</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (pathology)</term>
<term>Parkinson Disease, Secondary (physiopathology)</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Substantia Nigra (pathology)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Sympatholytics</term>
<term>Tyrosine 3-Monooxygenase (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease, Secondary</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Behavior, Animal</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease, Secondary</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Count</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Oxidopamine</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Sympatholytics</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias. We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000436 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000436 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:15094523 |texte= Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15094523" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |